Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey
- PMID: 15198130
- DOI: 10.1191/0269216304pm890oa
Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey
Abstract
Breakthrough pain (BKP) is a transitory flare of pain that occurs on a background of relatively well controlled baseline pain. Previous surveys have found that BKP is highly prevalent among patients with cancer pain and predicts more severe pain, pain-related distress and functional impairment, and relatively poor quality of life. An international group of investigators assembled by a task force of the International Association for the Study of Pain (IASP) evaluated the prevalence and characteristics of BKP as part of a prospective, cross-sectional survey of cancer pain. Fifty-eight clinicians in 24 countries evaluated a total of 1095 patients with cancer pain using patient-rated items from the Brief Pain Inventory (BPI) and observer-rated measures. The observer-rated information included demographic and tumor-related data, the occurrence of BKP, and responses on checklists of pain syndromes and pathophysiologies. The clinicians reported BKP in 64.8% of patients. Physicians from English-speaking countries were significantly more likely to report BKP than other physicians. BKP was associated with higher pain scores and functional interference on the BPI. Multivariate analysis showed an independent association of BKP with the presence of more than one pain, a vertebral pain syndrome, pain due to plexopathy, and English-speaking country. These data confirm the high prevalence of BKP, its association with more severe pain and functional impairment, and its relationship to specific cancer pain syndromes. Further studies are needed to characterize subtypes of BKP. The uneven distribution of BKP reporting across pain specialists from different countries suggests that more standardized methods for diagnosing BKP are needed.
Similar articles
-
An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain.Pain. 1999 Sep;82(3):263-274. doi: 10.1016/S0304-3959(99)00073-1. Pain. 1999. PMID: 10488677
-
Is balloon kyphoplasty better than percutaneous vertebroplasty for osteoporotic vertebral biconcave-shaped fractures?Acta Radiol. 2014 Oct;55(8):985-91. doi: 10.1177/0284185113511603. Epub 2013 Nov 26. Acta Radiol. 2014. PMID: 24280137
-
Breakthrough pain: characteristics and impact in patients with cancer pain.Pain. 1999 May;81(1-2):129-34. doi: 10.1016/s0304-3959(99)00006-8. Pain. 1999. PMID: 10353500
-
Breakthrough pain in cancer patients: characteristics, prevalence, and treatment.Oncology (Williston Park). 1998 Jul;12(7):1035-46; discussion 1049-52. Oncology (Williston Park). 1998. PMID: 9684277 Review.
-
Comparing complications of vertebroplasty and kyphoplasty for treating osteoporotic vertebral compression fractures: a meta-analysis of the randomized and non-randomized controlled studies.Eur J Orthop Surg Traumatol. 2015 Jul;25 Suppl 1:S77-85. doi: 10.1007/s00590-014-1502-4. Epub 2014 Jul 3. Eur J Orthop Surg Traumatol. 2015. PMID: 24989933 Review.
Cited by
-
Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study.Clin Drug Investig. 2013 Jun;33(6):391-400. doi: 10.1007/s40261-013-0079-8. Clin Drug Investig. 2013. PMID: 23605506 Clinical Trial.
-
Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP).Clin Transl Oncol. 2019 Mar;21(3):380-390. doi: 10.1007/s12094-018-1925-1. Epub 2018 Aug 9. Clin Transl Oncol. 2019. PMID: 30094793
-
Pain prevalence and treatment in patients with metastatic bone disease.Oncol Lett. 2019 Mar;17(3):3362-3370. doi: 10.3892/ol.2019.10013. Epub 2019 Feb 4. Oncol Lett. 2019. PMID: 30867771 Free PMC article.
-
Breakthrough pain in elderly patients with cancer: treatment options.Drugs Aging. 2014 Jun;31(6):405-11. doi: 10.1007/s40266-014-0181-5. Drugs Aging. 2014. PMID: 24817569 Review.
-
Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.Support Care Cancer. 2016 Jun;24(6):2669-75. doi: 10.1007/s00520-015-3056-3. Epub 2016 Jan 16. Support Care Cancer. 2016. PMID: 26780504 Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical